Pembrolizumab plus Chemotherapy in Lung Cancer
Pembrolizumab plus Chemotherapy in Lung Cancer
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
To the Editor:
In the KEYNOTE-189 trial, Gandhi et al. (May 31 issue)
1
compared pembrolizumab plus chemotherapy with chemotherapy alone in patients with untreated metastasic non–small-cell lung cancer. They concluded that patients with a tumor proportion score of 50% or more for programmed death ligand 1 (PD-L1) showed a greater benefit w...
Alternative Titles
Full title
Pembrolizumab plus Chemotherapy in Lung Cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2103675430
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2103675430
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMc1808567
